

1st Edelris Symposium on Affinity Selection-Mass Spectrometry in Drug Discovery

Programme

Confirmed Plenary Speakers (to Date)

Short break

1st Edelris Symposium on Affinity Selection-Mass Spectrometry in Drug Discovery

Programme

Wednesday June 2, 2021

Session Session 1

16:00 Opening & introduction

Dr Jean-Yves ORTHOLAND (EDELIRIS, Lyon, France)
Dr Allen ANNIS (AILERON THERAPEUTICS, Cambridge, United States)

16:10 Targeting RNA With Small Molecules Using Affinity-Selection Mass Spectrometry (KL01)

Dr Elliott B. NICKBARG
(MERCK & CO., INC., Boston, United States)

16:55 Discovery of Bioactive Natural Products Using Affinity Selection-Mass Spectrometry (PL01)

Prof. Richard VAN BREEMEN
(OREGON STATE UNIVERSITY, Corvallis, United States)

17:30 Short break

17:40 Accelerating Drug Discovery with the Integration of Affinity Selection Mass Spectrometry (PL02)

Dr Damian HOUDE
(RELAY THERAPEUTICS, Cambridge, United States)

18:15 Fishing from an Exclusive Pond Using AS-MS (PL03)

Dr Didier ROCHE
(EDELIRIS, Lyon, France)

18:30 Closing remarks Day 1

1st Edelris Symposium on Affinity Selection-Mass Spectrometry in Drug Discovery

Programme

Thursday June 3, 2021

Session Session 2

- 16:00 Opening remarks**
Dr Didier ROCHE
(EDELIRIS, Lyon, France)
- 16:05 Adapting the AS-MS Technology to GPCR Ligand Discovery (PL04)**
Prof. Wenqing SHUI
(SHANGHAITECH UNIVERSITY, Shanghai, China)
- 16:40 Lessons Learned from Pfizer's Experience in utilizing Affinity Selection by Mass Spectrometry for Hit Identification (PL05)**
Dr Matthew D. TROUTMAN
(PFIZER, Groton, United States)
- 17:15 Short break**
- 17:25 MALDI-TOF AS-MS – a Viable Alternative for LC-MS-based Workflows? (PL06)**
Dr Roman SIMON
(BOEHRINGER INGELHEIM PHARMA, Biberach/Riß, Germany)
- 18:00 Closing remarks & end of the conference**